Gastric lipase Inhibitors
1 drugsAbout Gastric lipase
Gastric lipase, secreted by chief cells in the stomach, initiates digestion of dietary fats, especially triglycerides. While pancreatic lipase is the major enzyme, gastric lipase is crucial in infants and those with pancreatic insufficiency.
Gastric lipase is a drug target for metabolic disorders, with inhibition reducing dietary fat absorption for weight loss. Currently, there is no genetic evidence directly linking gastric lipase to specific diseases.
Gastric lipase is targeted by one FDA-approved drug, XENICAL (orlistat), a small molecule from CHEPLAPHARM approved in 1999 for metabolic indications.
Top Gastric lipase Drugs
CHEPLAPHARM is the only company with an approved drug targeting gastric lipase.
Low competition suggests opportunity, but also highlights potential market risk and entry barriers.
Gastric lipase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Gastric lipase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Gastric lipase Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Gastric lipase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 10 | 4 | 2 | 4 | 67% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 9 | 6 | 2 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Gastric lipase Drug Approval Timeline (1999 - 1999)
The first and only drug, XENICAL, was approved in 1999.
The lack of recent approvals indicates potential saturation or challenges in developing new gastric lipase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 20 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Gastric lipase. A trial counts if an approved drug acting on Gastric lipase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.